PhRMA federal affairs
Former PhRMA Senior VP-Federal Affairs David Mohler will join the Washington, D.C. offices of law firm Foley Hoag as counsel to the Life Sciences and Government Strategies practices effective April 3. Mohler, who had worked in federal affairs at PhRMA between stints at Upjohn and Merck, returned to PhRMA in 2001 (1"The Pink Sheet" May 14, 2001, p. 36). After resigning on Jan. 3, Mohler was replaced by Alan Gilbert, who joined the association in May 2005 to be groomed for the position. Gilbert, a Capitol Hill veteran, most recently worked in the White House as special assistant to the President for health policy...
You may also be interested in...
David Mohler returns to Pharmaceutical Research & Manufacturers of America as deputy VP-federal affairs. Mohler previously served as a legislative counsel for the association, and was most recently in Merck's D.C. office. Former U.S. Chamber of Commerce health lobbyist Missy Jenkins is joining PhRMA as senior director-federal affairs. Jenkins was previously a staffer to former Rep. Gingrich (R-Ga.) and Sen. Simpson (R-Wyo.). Mohler and Jenkins will report to VP-Federal Affairs & Law Rodger Currie
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.